Alnylam Q1 product revenue $187M, GAAP loss $240M; lowers 2022 guidance to $870-930M

ALNYLAM PHARMACEUTICALS, INC.

2022-Q1 EPS reported -$2.00 revenue$213,259,000

Q1 total net product revenue $187M (+38% YoY); GAAP net loss $240M ($2.00 EPS), non-GAAP loss $180M ($1.49 EPS).
Lowered 2022 combined revenue guidance to $870-930M from $900M-$1B due to Q1 pandemic impact and non-recurring Q4 2021 benefits.
FDA extended vutrisiran NDA review to July 14, 2022; company expects launch upon approval if cleared.
Patient growth: ONPATTRO >2,200 (+7%), GIVLAARI >400 (+14%), OXLUMO >160 (+14%) QoQ.
Initiated Phase 1 for ALN-APP (Alzheimer's) and ALN-XDH (gout); filed patent suits against Pfizer/Moderna for COVID-19 vaccine lipids.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.